Can Ketamine Be Addictive? Dependence & Misuse

Yes, ketamine has real abuse and misuse potential, and problematic use can develop in some people. What that doesn't settle is whether medically supervised treatment for depression carries the same risk as frequent nonmedical use. The evidence points to important differences between those two situations.

Risk isn't a property of the molecule by itself. It depends on the dose, how often you're exposed, how the drug reaches you, who controls access to it, whether anyone is watching, and your own history with substances. Change those variables and you get very different pictures from the same drug.

Much of the research on ketamine-related harm studied people using it several times a week outside medical care. Those findings don't transfer directly to someone receiving a monitored infusion every few weeks. Both bodies of evidence are real, and they describe different situations.

Addiction, Dependence, and Tolerance Are Different Things

These four words get swapped around constantly, including by people who should know better. They describe different things.

Addiction, or substance use disorder, is a behavioral pattern. It involves impaired control over use, compulsive use, continuing despite harm to health, work, or relationships, and often strong cravings. It's defined by behavior and consequences, not by whether a drug produces physical effects.

Physical dependence means the body has adapted to regular exposure, so stopping produces withdrawal symptoms. This is not the same as addiction. People take medications for blood pressure and seizures that produce dependence without anything resembling compulsive use.

Tolerance means needing more exposure to get the same effect. It's worth splitting apart, because tolerance to anesthesia, to subjective or dissociative effects, to recreational effects, and to an antidepressant response are separate questions. There's no reason to assume they develop at the same pace, and the evidence treats them separately.

Misuse means using the medication outside the prescribed or supervised plan. Taking more than directed, taking it more often, or obtaining it elsewhere all count. Misuse can happen without addiction, and it's the most common practical concern in a treatment setting.

Why Ketamine Has Abuse and Misuse Potential

Ketamine produces dissociation and altered perception quickly, and some people find those effects rewarding. Spravato's labeling describes an abuse potential study in 34 recreational polydrug users who had experience with perception-altering drugs. Single doses of intranasal esketamine and of intravenous ketamine produced higher Drug Liking and Take Drug Again scores than placebo in that group.

That study measured abuse potential in people already familiar with these effects, so it doesn't describe how patients respond in ordinary treatment. What it does establish is that esketamine carries genuine abuse potential.

A drug that acts fast and feels notable to some users has abuse potential, particularly when someone can repeat the experience whenever they choose. That last condition is the one a treatment setting changes.

Is Ketamine a Controlled Substance?

Yes. Ketamine has been a Schedule III controlled substance under the federal Controlled Substances Act since 1999, and that includes its isomers. Esketamine, the molecule in Spravato, is also Schedule III.

Schedule III means a drug has an accepted medical use along with a potential for abuse that's lower than Schedule I or II substances and higher than Schedule IV. The scheduling is a statement about the drug and its recognized medical role. It says nothing about any individual patient's likelihood of developing a problem.

What Does the Spravato Label Say About Abuse and Misuse?

Spravato's boxed warning names abuse and misuse directly. It says the drug has the potential to be abused and misused. Prescribers are told to weigh risks and benefits before using it in patients at higher risk of abuse, and to monitor for signs of abuse and misuse.

The warnings section adds that esketamine is a Schedule III substance that may be subject to abuse and diversion. It instructs clinicians to assess each patient's risk before prescribing and to monitor everyone during treatment for drug-seeking behavior. On substance use history, the label says people with a history of drug abuse or dependence are at greater risk, and directs careful consideration and monitoring. It does not tell clinicians to refuse them.

Spravato is available only through a restricted program called the SPRAVATO REMS. The medication is dispensed and administered in certified healthcare settings, taken by the patient under direct observation, followed by at least two hours of monitoring. Worth noting: the REMS exists for several risks together, including sedation, dissociation, and respiratory depression, not for abuse alone.

How Medically Supervised Ketamine Differs From Recreational Use

The difference isn't that clinical ketamine is a different chemical. It's that nearly every variable that drives risk is controlled by someone other than the person taking it.

Doses are measured and consistent rather than guessed. Sessions happen on a schedule instead of whenever the urge arrives. Someone screens you first, watches you during, and reassesses whether treatment is still working. Access is limited, which removes the option of using more because a day went badly.

None of that means supervised treatment carries zero risk of problematic use. It means the setting removes most opportunities for uncontrolled use and puts a trained observer in the position to notice a developing pattern early. Our guide on whether ketamine therapy is safe covers the rest of what monitoring is for.

Can You Develop Tolerance to Ketamine?

Both labels report that tolerance can develop with prolonged use, and that finding comes largely from anesthesia and from heavy repeated exposure. In those contexts, higher doses become necessary for the same effect.

The question most patients actually have is different: does ketamine stop working for depression? The evidence doesn't support that as an inevitability. Studies of repeated and maintenance infusions generally find that benefits are sustained while treatment continues, and that symptoms return after treatment stops. Relapse when a treatment ends is not the same phenomenon as tolerance to it. Our guide on the long-term effects of ketamine therapy covers what happens over months and years of treatment.

That distinction matters clinically. If treatment seems to be losing effect, that's information for your provider rather than a reason to seek more on your own. Sometimes the answer is a different schedule.

Can Ketamine Cause Physical Dependence or Withdrawal?

Physical dependence has been reported with prolonged ketamine use, and both prescribing labels say so. The exposure pattern attached to that finding is specific and worth quoting closely. Withdrawal symptoms have been reported after stopping frequently used large doses taken over long periods, with frequently used meaning more than weekly.

The symptoms reported with daily large-dose intake are craving, fatigue, poor appetite, and anxiety. That exposure pattern differs substantially from intermittent medically supervised treatment.

Spravato's labeling adds that no withdrawal symptoms were captured up to four weeks after cessation of esketamine treatment in its clinical program. Long-term esketamine studies have also not identified a trend suggesting drug abuse or dependence during monitored treatment. Both findings are reassuring rather than conclusive, since trial populations and supervised settings may not reflect every real-world patient.

If you're using ketamine frequently outside medical supervision and want to stop, the right move is an evaluation by a clinician who treats substance use. Stopping is easier with support, and a clinician can look at everything else going on.

What Does Problematic Ketamine Use Look Like?

These patterns are worth knowing, because noticing them early makes them easier to address:

Using more often, or in larger amounts, than intended
Looking for ketamine outside your treatment plan
Increasing use without a clinician directing it
Strong urges or cravings between sessions
Continuing despite harm to health, finances, work, relationships, or mood
Using for reasons drifting further from the original treatment goal
Hiding use from people close to you or from your provider
Getting ketamine from more than one source

One item on this list isn't a diagnosis. Substance use disorder is diagnosed by a clinician looking at a pattern over time, and it's a medical condition rather than a character problem.

Bladder and Urinary Problems With Frequent Ketamine Use

This is the best-documented harm from heavy ketamine use, and the evidence base is mostly recreational. Among people who use ketamine regularly, roughly a quarter report lower urinary tract symptoms. Ketamine injection labeling describes cystitis, reduced bladder capacity, ureteral stenosis, ureteral obstruction, and hydronephrosis with long-term use or abuse. In severe cases this progresses to permanent bladder damage and kidney problems.

Therapeutic treatment looks different. A 2025 systematic review of 27 studies of ketamine given for psychiatric conditions found reported urological symptoms ranging from zero to 24.5 percent across studies, generally mild or moderate.

That range is not an incidence rate caused by treatment. Studies measured urinary outcomes differently, and many relied on patients volunteering symptoms rather than systematic screening. Control groups sometimes reported similar or higher rates, and only 15 percent of the studies carried a low risk of bias.

The reviewers concluded that current treatment data do not show a clear elevated risk of urinary symptoms, while long-term evidence remains insufficient. Most studies followed patients for about a month. New urinary symptoms are worth reporting promptly so the treatment team can evaluate them before they become more serious.

Liver and Other Risks From Repeated Heavy Exposure

Ketamine injection labeling notes an association between ketamine and hepatobiliary dysfunction with recurrent use. Notably, the label includes medically supervised use for unapproved indications in that description, not only misuse. Some clinics check liver function for patients on longer treatment courses for this reason.

Repeated heavy recreational use has also been associated with problems in memory and attention. Whether standard psychiatric protocols produce meaningful cognitive effects is a separate question with a much weaker signal, and general side effects are covered in our guide on ketamine therapy side effects.

What If You Have a History of Substance Use Disorder?

A history of addiction does not automatically disqualify anyone from ketamine or Spravato. Spravato's labeling identifies these patients as higher risk and calls for careful consideration and monitoring, which is a very different instruction from exclusion.

A thoughtful clinician weighs current substance use, how stable recovery is, and any past experience with ketamine specifically. They also consider whether cravings are active now, what treatment supports exist, and whether the expected benefit justifies the added risk. Depression and substance use disorders co-occur constantly, so this comes up often.

It's worth knowing that many ketamine trials excluded people with substance use disorders, which means the research base for this group is thinner than it should be. Our guide on who shouldn't get ketamine therapy covers how these decisions get made.

Is Spravato Less Likely to Be Misused Than At-Home Ketamine?

The difference here is about access, not about one treatment being more responsible than another. Spravato is given in a certified setting under observation through its REMS, and patients don't take doses home. In-person IV or IM ketamine limits unsupervised access during dosing in much the same way.

Prescribed at-home ketamine puts medication in someone's possession between appointments, which is a different access environment. That difference doesn't demonstrate that at-home treatment leads to misuse. It means the safeguards sit elsewhere: in patient selection, prescribing practices, quantities dispensed, monitoring, storage, and treatment frequency.

Does Needing Maintenance Treatment Mean You're Dependent?

No, not by itself. This confusion causes real distress, so it's worth being clear.

If your depression returns weeks after treatment stops, that's the underlying condition reasserting itself. Symptoms returning when treatment is stopped do not, by themselves, mean someone is experiencing withdrawal or addiction. Depression is often a recurring illness, and needing ongoing treatment for a recurring illness is ordinary.

Addiction involves impaired control, compulsion, and use that causes harm. Wanting a scheduled treatment because it keeps you functional is none of those things. What would concern a clinician is different: wanting sessions closer together without your symptoms justifying it, or feeling pulled toward ketamine between appointments.

How Clinics Reduce Misuse Risk

Responsible practices look fairly consistent across good providers. They take a substance use history rather than skipping the awkward questions. They set treatment frequency by clinical need instead of by request. They reassess whether treatment is still helping, and they notice when someone asks for escalating frequency without a clinical reason behind it.

For Spravato, some of this is required rather than optional. Certified settings, supervised administration, and the two-hour monitoring period are REMS requirements. For off-label ketamine there's no equivalent federal framework, so the quality of screening varies by clinic, which is one reason choosing carefully matters.

When to Talk to Your Treatment Provider About Ketamine Use

Bring it up if you're thinking about ketamine between scheduled treatments, if you want sessions more and more often, or if you're getting ketamine from another source. The same goes for developing cravings, increasing your use without your clinician's direction, or noticing urinary symptoms.

Also say something if treatment seems less effective and you find yourself tempted to increase exposure on your own. That's the moment when a conversation helps most, and providers who do this work well have heard it before.

Finding a Clinic That Takes Misuse Risk Seriously

Screening isn't a hurdle put in your way. A provider who asks careful questions about substance use is doing the job properly, and one who never raises the subject is skipping something important.

A good provider can tell you how they assess substance use history, how they decide treatment frequency, and how they measure whether treatment is working. They can also say what would make them pause or stop. Vague answers to those questions are worth noticing.

If you're looking for a provider, you can search ketamine clinics near you, or browse Spravato treatment centers and IV ketamine infusion clinics. Our guide on who is a good candidate for ketamine therapy covers the broader screening picture.